Summary of the recommendations of the <scp>EFNS</scp>/<scp>MDS</scp>‐<scp>ES</scp> review on therapeutic management of <scp>P</scp>arkinson's disease

Ferreira, Joaquim J.; Katzenschlager, Regina; Bloem, Bernard; Bonuccelli, Ubaldo; Burn, David J.; Deuschl, Günther; Dietrichs, Espen; Fabbrini, Giovanni; Friedman, Andrzej; Kaňovský, Petr; Kostić, Vladimir; Nieuwboer, Alice; Odin, Per; Poewe, Werner; Rascol, Olivier; Sampaio, Cristina; Schüpbach, Michaël; Tolosa, Eduardo; Trenkwalder, Claudia; Schapira, Anthony H.V.; Berardelli, Alfredo; Oertel, Wolfgang H.

doi:10.1111/j.1468-1331.2012.03866.x

Cited by 310 publications

(254 citation statements)

References 354 publications

(366 reference statements)

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…However, there is still no consensus on exactly how such treatment should be administered. Evidence‐based reviews conclude that there are different well‐documented treatment strategies, but there is no evidence that one strategy should be chosen over another 7, 8, 9, 10, 11, 12, 75. Therefore, it is important to treat each patient individually.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, most treatment strategies also aim at delaying the evolvement of motor fluctuations as long as possible. Various treatment recommendations and guidelines are available, from individual authors and from national and international associations and specialist groups 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19. Some of these are evidence based, like the recently published national guidelines from Germany and Sweden,18, 19 while many others are based on consensus in expert groups.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Algorithms for the treatment of motor problems in Parkinson's disease

Dietrichs

Odin

2017

Acta Neurol Scand

Self Cite

View full text Add to dashboard Cite

Several different strategies are effective for medical treatment of motor problems in Parkinson's disease (PD). Many guidelines and evidence‐based reviews are available, but there is no documentation or consensus in favor of just one treatment strategy. This review presents two algorithms that may be helpful when deciding how to treat a PD patient at various stages of the disease. The first algorithm suggests one way to treat PD from the first onset of motor symptoms. It is largely based on treatment recommendations from the Scandinavian countries and Germany. The other algorithm is meant as assistance for choosing among the different device‐aided treatments for advanced PD. There is not sufficient comparative data to recommend one particular line of treatment, neither in early PD nor in advanced disease with motor complications. Individualized treatment is needed for each patient. The current algorithms only represent an alternative for aiding treatment decisions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Algorithms for the treatment of motor problems in Parkinson's disease

Dietrichs

Odin

2017

Acta Neurol Scand

Self Cite

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7] Data from open trials and case reports suggest limited benefi t. [8][9][10][11] Several national and international guidelines state that modafi nil should be considered in the management of PD-related somnolence, recognizing that evidence is confl icting with improvement noted in subjective sleep ratings but inconsistent or no benefi t observed in objective sleep parameters. 2,3,12,13 Evaluating the same published clinical data, the Scottish Intercollegiate Guidelines Network does not recommend the use of modafi nil in the management of excessive daytime sleepiness. 14 …”

Section: Resultsmentioning

confidence: 99%

Modafinil: Parkinson Disease–Related Somnolence

Generali

Cada²

2014

Hosp Pharm

View full text Add to dashboard Cite

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

show abstract

“…In the majority of cases, adding/increasing third-generation dopamine agonists, MAO-i or COMT-i [61] are effective in reducing symptoms of LTS. In more advanced patients, however, alternative therapies such as deep brain stimulation (DBS) or continuous drug infusion are advised [61].…”

Section: The Influence Of Dopaminergic Drugs On Cognitive Impairment mentioning

confidence: 99%

Levodopa/Carbidopa Intestinal Gel for Treatment of Advanced Parkinson’s Disease: An Update on the Effects of Cognitive Functions

Latino¹,

Tagliente²,

Pellicano³

et al. 2017

APD

View full text Add to dashboard Cite

Cognitive impairment is a frequent non-motorsymptom of Parkinson's disease (PD). In early disease stage, this takes the features of dysexecutive syndrome, and is mostly dependent on derangement of frontostriatal circuitries. In advanced stages, worsening of dysexecutive symptoms is accompanied by disorientation and memory deficit leading to dementia in 30% of cases, due to multiple neurotransmitter derangement. Dysexecutive symptoms in the early stages of PD may benefit from dopamine replacement therapy (DRT). Conversely, severe cognitive symptoms in more advanced stages are frequently aggravated by DRT. In particular, pulsatile stimulation of dopaminergic receptors by orally administered levodopa (LD) plays a significant negative role on cognitive and neuropsychiatric symptoms in advanced PD. The introduction of a gel of LD-carbidopa for continuous intestinal administration (LCIG) allows marked stabilization of plasma LD concentrations and provides benefit on motor fluctuations and dyskinesia of significantly greater magnitude than conventional oral administration in advanced PD patients. The results from several preliminary studies suggest that efficacy of LCGI on motor symptoms may be accompanied by good tolerability and potential benefit on several non-motor symptoms, including cognitive impairment. Future studies with longer observation period and larger cohorts are advised to confirm these preliminary observations.

show abstract

Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease

Cited by 310 publications

References 354 publications

Algorithms for the treatment of motor problems in Parkinson's disease

Algorithms for the treatment of motor problems in Parkinson's disease

Modafinil: Parkinson Disease–Related Somnolence

Levodopa/Carbidopa Intestinal Gel for Treatment of Advanced Parkinson’s Disease: An Update on the Effects of Cognitive Functions

Contact Info

Product

Resources

About